Dow Jones 9765.35 +27.56 8:14 am PST, November 12, 2003  NASDAQ 1946.26 +15.51 For info, visit access.smallcapnetwork.com S & P 500 1049.74 +3.17 To be removed, please click here Russell 2000 534.55 +5.98 VOLUME 03: ISSUE 71  BioCurex adds China. Opportunities in C-CHIP. We brought you a Trading Alert on BioCurex (OTC:BB BOCX) three weeks ago when the stock was trading at 17 cents.  Currently, the shares are trading at around 30 cents--pretty close to a standup double. Nevertheless, we believe that there is much more upside to come. (see attached press release). We continue to recommend accumulation for risk oriented investors. In late October, the shares of BioCurex hit 42 cents as investors began accumulating positions. The subsequent pullback seems fairly complete and traders will note that the levels tested are higher than the previous lows--a favorable trading sign. The volume remains impressive with good two-way trade and the price seems to be basing in the 28-30 cent range.  As you can see by the attached Press Release, BioCurex continues to move forward: recently adding a China patent for its RECAF cancer detection technology to go along with previous patents granted in the US, Australia and Russia. What does this mean? Simply, it means that licensee partners will have a clear field in the aforementioned regions and, once granted, patents in 21 other countries to enhance BioCurex's and its future partners' global market penetration. China (and 21 others) beckon The China patent is a big deal for BioCurex. The healthcare markets in most of Asia aren't even close to the maturity of those in the West, and the potential is enormous. Factors driving the Chinese healthcare market include an aging population, improving living standards due to a gradual transition into a free market society, and enhanced health awareness. These facts can be expected to result in increased business opportunities for U.S. pharmaceutical, biotech and medical device companies. The pharmaceutical industrial revenue in China is currently about $20 billion. In accordance with World Trade Organization (WTO) regulations, China has committed itself to cutting tariffs, liberalizing its domestic distribution practices, and restructuring its regulatory environment. Over the next three years, China will allow foreign enterprises to import products and engage in distribution services. Further, China has implemented new drug administration laws designed to streamline product registration and protect Intellectual Property Rights (IPR). Over the next 5-10 years this market should be able to provide enormous returns. If anything, BioCurex is slightly early in China. That said, early is strategically better--and more profitable, ultimately --than late. Having these patents on board will only strengthen the company's bargaining position in deals with licensees, which we expect it will begin to announce over the next 6-12 months.  As we have stated, while there is greater risk associated with accumulating the shares now, once the first licensing announcement is made the shares will likely be markedly higher than current levels.   BOCX PRESS RELEASE China Grants BioCurex's RECAF Patent: Largest Population Country In The World Approves Technology Wednesday November 12, 8:05 am ET  RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--Nov. 12, 2003--BioCurex Inc. (OTCBB:BOCX - News) is pleased to announce that a patent for its proprietary RECAF(TM) technology for cancer diagnosis has been approved and granted in the People's Republic of China. The patent covers the technologies used in the Company's Histo-RECAF(TM) and Cryo-RECAF(TM) kits as well as (Serum-RECAF(TM)) a cancer diagnostic blood test. Further, the patent protects other cancer diagnostic applications such as leukemia to be developed in a near future.  Dr. Ricardo Moro, BioCurex's CEO stated: "China's healthcare market is one of the most dynamic and rapidly changing in the world and that creates abundant opportunities for foreign companies. The Chinese healthcare market is generally underestimated. For example, China is now estimated to have more CT instruments than the United States. The healthcare industry in China has posted double-digit (16 percent) average growth, annually, for a decade. China's transition into a free market economy, coupled with drastic reforms in the health sector and intellectual property protection have increased business opportunities for small and medium-sized foreign pharmaceutical, biotechnology and medical companies." In-vivo RECAF(TM) applications, such as cancer imaging, therapy and vaccination remain pending under a continuation in part of the original application. Similar patents have already been issued in the United States, Australia and Russia and they are pending in most European countries, Canada and Japan.  According to a report from Genesis Technology Group, China's drug sales reached US$6.8 billion in 2002, and are expected to rise toUS$14 billion in 2005 and to US$24 billion in 2010. The pharma revenue in China is about US$20 billion, of which approximately 48%, 30% and 22% come from the sales of joint venture, domestic and imported products, respectively. The size of the industry will equal that of the United States by 2020.  The Globoscan 2000 cancer database states that there are about 1.9 million new cases and about 1.4 million deaths annually from cancer in China. With a population of approximately 1.3 billion, China is a vast market for cancer therapies. Cancer became the main cause of death in China in 1996.  China is the fastest growing pharmaceutical market in the world and currently ranks as the ninth largest pharmaceutical market with nearly US$7 billion in sales in 2001. China's changing healthcare environment is designed to extend basic health insurance to a largerportion of the population and give individuals greater access to products and services.  About BioCurex:  BioCurex Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAF(TM) kits provide proof of concept for the RECAF technology. Detailed information about BioCurex may be obtained from its Web site.  Note:  The company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results could differ materially from expected results.  ------------------------------------------------------------------------ Contact:       BioCurex Inc.      Dr. Ricardo Moro, 866-884-8669, Fax: 866-437-2277     info@biocurex.com   C-CHIP weakens.... for now. A fair bit of mail regarding our last trading alert on telematics firm C-CHIP (OTCBB: CCHI). Our Alert price was 86 cents and while the shares did a lot of trade around that level, they have sold off a bit and now change hands at around 70 cents. Most of our readership understands the nature of both the stocks we look at and our approach. However, some points need reiteration. We follow, for the most part, early stage small to micro-cap companies. These stocks will be volatile, as more investors get involved. If you can't take the stress, either don't participate, or set a sell stop at your risk (read: pain) threshold. Never purchase a large whack of shares at the outset. When we suggest 'begin accumulating' we aren't kidding. Just begin... Never bet the farm. Keep financial commitments for these types of companies to a 'few acres' at most. Relax. If you follow those simple rules, your trading strategy will become clear (er). C-CHIP is an exciting, early stage technology concern. The prospects and potential for significant market penetration are very compelling. But, it won't happen tomorrow or even over the next month. Smallcap investors' best strategy is patience. Just because the price roils around doesn't mean the story isn't sound. It just means that others may have different ideas to yours.  That's what makes a market. Those shareholders that are selling C-CHIP at this level may well continue to sell even if the shares happen to go lower. But, if you like the company's story (we do), view the weakness as an opportunity and add to positions. If not, avoid it, or sell it and purchase something else. For our part, we believe C-CHIP will be able to execute its business plan successfully in the reasonably near future. Perhaps you might want to re-read our C-CHIP Trading Alert. We think C-CHIP's prospects are most compelling whether you bought it at 90 cents, 70 cents, or even lower--if that comes to pass. At this point in the long-term process, price is, frankly, somewhat irrelevant. Here's the deal: Remember last November when we brought you CEL-SCI (AMEX: CVM) at 20 cents? For six months, the shares didn't do squat. Now? At $1.40 the shares have risen 600 percent. In mid-October the shares hit $1.75. Patience tends to be rewarded for those willing to assume the risks when coupled with good due diligence and a disciplined trading strategy.   Need another reason to Sign up for your FREE Preferred Membership? Over the past year, we've brought you 13 Trading Alerts. If you had invested $1000 in each one, your $13,000 investment would have grown to $23070, if you had sold, say, last Friday, to pick a day. That's a 78 percent return in a less than a year. The best? Obviously, Cel-Sci. The worst? ThinkPath. If we strip those two out--the highest and lowest returns--the return on your $11,000 investment would have been a very respectable 51 percent. Not too shabby. By comparison, the S&P index has returned about 20 percent over the last year. The NASDAQ--to which we also alerted you at the low in March 2003--has returned around 40 percent in the same period.  The NASDAQ Tracker (NASDAQ: QQQ) did slightly better than its benchmark having risen 45 percent. Oh yes, we told you about that one, too at $24 in February 2003. Now it's $35. And we're only looking at Trading Alerts. I suspect if we included all of our Company Profiles (check our Track Record), the numbers would likely have been even better. The best is yet to come. Sign up NOW! Joining our NEW Preferred Member Program is easy and simple. Just follow this quick two-step process: Opt-in your email address, then, make sure and confirm the request for confirmation you will receive in your inbox. That's it! You'll automatically be in position to start receiving these new special features available only to Preferred Members! To subscribe to the preferred member list, simply click here. Or, to subscribe by email, send a blank email to scn-preferred-subscribe@delta.levelogic.com. If there is a problem with the subscription or you do not receive a confirmation email within 2 hours, go to http://access.smallcapnetwork.com/pref-sub.html and submit your email address.   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com Unsubscribe Here D I S C L A I M E R : The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and 200,000 newly issued restricted shares by C-Chip Technologies for coverage of the company. Additionally, TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.